Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck

ClinicalTrials.gov ID: NCT00216138

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00216138. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 8:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): Hoosier Oncology Group HN02-40

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Recent progress in treatment of recurrent/metastatic SCCHN has been made with the introduction of the taxanes. Docetaxel as a single agent has a response rate of 22-42% and 17% in patients with recurrent disease. Capecitabine is an oral fluoropyrimidine prodrug that is converted into 5-FU. Previous studies have shown that the capecitabine/docetaxel combination has a synergistic inhibition of tumor growth, resulting in significantly superior efficacy in time to disease progression (TTP), overall survival, median survival and objective tumor response rate compared to docetaxel alone. This trial will investigate the efficacy the combination of docetaxel and capecitabine in treating patients with recurrent/metastatic SCCHN.

Study identification

NCT ID
NCT00216138
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Enrollment
19 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2004 (Type not available)
Primary completion
Sep 2007 (Actual)
Completion
Sep 2007 (Actual)
Last update posted
May 2, 2011

2004 – 2007

United States locations

U.S. sites
18
U.S. states
7
U.S. cities
16
Facility City State ZIP Site status
Helen F. Graham Cancer Center Newark Delaware 19713 —
University of Chicago Chicago Illinois 60637 —
Elkhart Clinic Elkhart Indiana 46515 —
Oncology Hematology Associates of SW Indiana Evansville Indiana 47714 —
Fort Wayne Oncology & Hematology, Inc Fort Wayne Indiana 46815 —
Center for Cancer Care at Goshen Health System Goshen Indiana 46527 —
Indiana University Cancer Center Indianapolis Indiana 46202 —
Quality Cancer Center (MCGOP) Indianapolis Indiana 46202 —
Arnett Cancer Care Lafayette Indiana 47904 —
Medical Consultants, P.C. Muncie Indiana 47303 —
Center for Cancer Care, Inc., P.C. New Albany Indiana 47150 —
Northern Indiana Cancer Research Consortium South Bend Indiana 46601 —
Providence Medical Group Terre Haute Indiana 47802 —
AP&S Clinic Terre Haute Indiana 47804 —
Dana Farber Cancer Institute Boston Massachusetts 02115 —
Center for Hematology-Oncology of S Michigan Jackson Michigan 49201 —
Siteman Cancer Center St Louis Missouri 63110 —
Methodist Cancer Center Omaha Nebraska 68114 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00216138, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 2, 2011 · Synced Nov 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.